Karuna Therapeutics sees broad possibilities for its novel schizophrenia drug


The new CEO of Karuna Therapeutics Inc. has big plans in mind for KarXT, the company's novel schizophrenia drug.

Previous Jimmyluka's closes its Parsons Avenue restaurant, teases something new
Next The stock market had a rough 2022. Here's how Charlotte's biggest companies performed